@article{3098729,
    title = "Plasma C-reactive protein and risk of cancer: A prospective study from
Greece",
    author = "Trichopoulos, D and Psaltopoulou, T and Orfanos, P and Trichopoulou, A and and Boffetta, P",
    journal = "Cancer Epidemiology, Biomarkers & Prevention",
    year = "2006",
    volume = "15",
    number = "2",
    pages = "381-384",
    publisher = "AMER ASSOC CANCER RESEARCH",
    issn = "1055-9965, 1538-7755",
    doi = "10.1158/1055-9965.EPI-05-0626",
    abstract = "Background: Inflammation is an important component of carcinogenesis but
little research has been conducted on whether inflammation markers can
be predictive of cancer risk in humans.
Methods: We analyzed C-reactive protein (CRP), a marker of inflammation,
in plasma samples of 496 cases of cancer and 996 controls selected among
participants in a prospective study from Greece.
Results: Plasma CRP level was higher in cancer cases than controls (odds
ratio for increase in CRP level of 3.2 mg/L, 1.20; 95% confidence
interval, 1.10-1.32): The corresponding odds ratio after exclusion of
the first year of follow-up and of individuals with CRP level above 20
mg/L was 1.32 (95% confidence interval, 1.15-1.52). Although based on
small number of cases, the association between elevated plasma CRP level
and risk was stronger for cancers of the liver, lung, skin, kidney, and
bladder, as well as for lymphoma and leukemia than for other neoplasms.
Conclusions: Our results confirm the important role of inflammation in
human cancer and suggest that plasma CRP level is a potential marker of
increased cancer risk."
}